Smoking Cessation Aids Market Global Analysis & Forecast 2028

report image

Smoking Cessation Aids Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Nicotine Replacement Therapy, Drugs, Electronic Cigarettes, and Others) and End-User (Hospital Pharmacies, Online Channel, Retail Pharmacies, and Other End Users)

Publication Month: Aug 2021 | Report Code: TIPRE00023325 | No. of Pages: 156 | Category: Pharmaceuticals | Status: Published

The Smoking Cessation Aids market is expected to reach US$ 64,032.30 million in 2028 from US$ 23,413.08 million in 2021. The market is estimated to grow with a CAGR of 15.5% from 2021 to 2028.

Key factors that are driving the growth of this market are rising addiction toward tobacco smoking, increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.


Lucrative Regions for Smoking Cessation Aids Market

Lucrative Regions for Smoking Cessation Aids Market

Get more information on this report :

Market Insights

Rising addiction of tobacco smoking

Nicotine is a highly addictive substance found in tobacco plant. The smoking of tobacco is proven to be dangerous in all forms as it can lead to chronic health conditions, preventable diseases, deaths, and disabilities. According to the World Health Organization (WHO), smoking-related disorders result in about 435,000 deaths per year in the US, which equals to around 1 in 5 of the total deaths in the country. According to the Centers of Disease Control and Prevention (CDC), in 2018, nearly 40 million adults in the US smoked cigarettes. Moreover, about 4.7 million middle and high-school students used at least one tobacco product and around 1,600 young population below the age of 18 in the US smoked their first cigarettes. Every year, nearly half a million patients die due to illness caused by smoking. The US government spends ~US$ 225 billion for medical care to treat patients suffering from smoking-associated conditions in the US. Therefore, prevalence of tobacco smoking is high across various countries in the world.
The scenario is similar in various European and Asian countries. Greece, Bulgaria, France, and Croatia comprise the high tobacco consuming populations in Europe. According to the Institute of Health Metrics and Evaluation, smoking is a very common addiction in Europe as over 20% adults over the age of 15 smoke every day. Furthermore, according to the World Population Review, the highest smoking rates are found in Southeast Asia and Balkan in Europe. The WPR also suggests that in various South and Southeast Asian countries, the smoking rates tend to be high among men. For instance, in Indonesia, the smoking rate among males was 76.20% in 2018. Thus, the rising number of smoking populations across the world drives the growth of the global smoking cessation aids market.

Product-Based Insights

Based on product, the smoking cessation aids market is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. E-cigarettes are considered as a healthy alternative to tobacco cigarettes and is estimated to be the fastest growing segment over the forecast period. E-cigarettes are an effective alternative for reducing health conditions associated with tobacco, while nicotine replacement therapies work best for smoking cessation. E-cigarettes are a potential threat to tobacco-based cigarettes. In addition, Consumption of e-cigarettes are less harmful compared to the regular cigarettes, no smoke and no risk of passive smoking, allowed to use even in no-smoking places, varying nicotine levels, and availability in various flavors are some of the major driving factors for the e-cigarettes market. in addition, the increasing popularity of e-cigarettes backed by its electronic feature is the major factor contributing towards its increasing demand.

Smoking Cessation Aids Market, by Product – 2021 and 2028

Smoking Cessation Aids Market, by Product – 2021 and 2028

Get more information on this report :

End User-Based Insights

Based on end-user, the smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other end users. The retail pharmacies segment is likely to hold the largest share of the market in 2021, however the online channel segment is anticipated to register the highest CAGR of the market during the forecast period.

Strategic Insights

Report Coverage - Smoking Cessation Aids Market
Report CoverageDetails
Market Size Value inUS$ 23,413.08 Million in 2021
Market Size Value byUS$ 64,032.30 Million by 2028
Growth rateCAGR of 15.5% from 2021-2028
Forecast Period2021-2028
Base Year2021
No. of Pages156
No. of Tables58
No. of Charts & Figures70
Historical data availableYes
Segments coveredProduct and End-User
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The key players such as Pfizer Inc.; GlaxoSmithKline plc.; Dr. Reddy's Laboratories; Johnson and Johnson Services, Inc.; Cipla Inc.; Perrigo Company plc; Bausch Health Companies Inc.; Glenmark; NJOY; and Juul Labs adopt several organic and inorganic strategies to enhance their revenue and market standings. For instance, in July 2020, Dr Reddy’s Laboratories launched of over-the-counter Nicotine Polacrilex lozenges in the American market in the strengths of 2 mg and 4 mg. Moreover, in November 2020, Perrigo Company plc completed its the fourth year of its “Quitting is Better” campaign in partnership with the American Cancer Society (ACS).

Smoking Cessation Aids Market – by Product

  • Nicotine Replacement Therapy
  • Drugs
  • Electronic Cigarettes
  • Others

Smoking Cessation Aids Market – by End User

  • Hospital Pharmacies
  • Online Channel
  • Retail Pharmacies
  • Others

Smoking Cessation Aids Market – by Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East and Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East &Africa
  • South and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of South and Central America

Company Profiles

  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Dr. Reddy's Laboratories
  • Johnson and Johnson Services, Inc.
  • Cipla Inc.
  • Perrigo Company plc
  • Bausch Health Companies Inc.
  • Glenmark
  • NJOY
  • Juul Labs

Frequently Asked Questions

Smoking cessation lowers the risk of cancer and other serious health problems. Some products contain nicotine as an active ingredient and others do not. Counseling, behavior therapy, medicines, and nicotine-containing products, such as nicotine patches, gum, lozenges, inhalers, and nasal sprays, may be used to help a person quit smoking.
The factors that are driving and restraining factors that will affect Smoking Cessation Aids Market in the coming years. Factors such as rising addiction toward tobacco smoking, increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.
The Smoking Cessation Aids Market majorly consists of the players such as Pfizer Inc., GlaxoSmithKline plc., Dr. Reddy's Laboratories, Johnson and Johnson Services, Inc., Cipla Inc., Perrigo Company plc, Bausch Health Companies Inc., Glenmark, NJOY, Juul Labs among others amongst others.
The US is the largest market for Smoking Cessation Aids at a global level. The market's growth is attributed to the Increasing implementation of various tobacco control programs, high expenditure in healthcare and wellness by the countries in the region and launch of new and innovative products by market players for smoking cessation are some of the factors likely to drive the Smoking Cessation Aids market in the region. According to CDC, in 2017, 14 of every 100 US adults aged 18 years or older (14.0%) currently smoke cigarettes. This hints at a high usage of de-addiction products. Also, this depicts the growing awareness of the people and their readiness to quit smoking. There are also non-government and government establishments working to educate and help people quit smoking that is engaged dedicatedly, to bring the number of smokers down.
The global Smoking Cessation Aids market based on product is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. In 2021, the electronic cigarettes segment held the largest share of the market, by product. The electronic cigarettes segment of Smoking Cessation Aids Market is also expected to witness fastest CAGR during 2021 to 2028.The increasing number of campaigns to reduce smoking and tobacco dependence are likely to increase the demand for the above-mentioned products. Therefore, it is expected that market is likely to propel during the forecast period.
Asia Pacific is expected to be the fastest-growing region and is likely to expand at a high growth rate due to increasing awareness about the smoking cessation and nicotine de-addiction products, and a huge population base in the region. For instance, an international collaboration of researchers, led by those from Vanderbilt University in the United States, studied the trends in tobacco use in China, Japan, South Korea, Singapore, Taiwan, and India in Tobacco Smoking and Mortality in Asia, a pooled meta-analysis published by JAMA Network in March 2019. By 2030, it is anticipated that 8.3 million fatalities would be due to smoking. China, India, and Indonesia account for half of the world's male smokers, and Asia is the world's largest tobacco user and production.

The List of Companies - Smoking Cessation Aids Market

  1. Pfizer Inc.
  2. GlaxoSmithKline plc.
  3. Dr. Reddy's Laboratories
  4. Johnson and Johnson Services, Inc.
  5. Cipla Inc.
  6. Perrigo Company plc
  7. Bausch Health Companies Inc.
  8. Glenmark
  9. NJOY
  10. Juul Labs
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Smoking Cessation Aids Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Smoking Cessation Aids, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount